The Mobius MyWay portfolio allows ordering of ready-to-use, gamma-irradiated single-use assemblies with increased design flexibility, supply predictability and shorter lead times. (Credit: MillaporeSigma)
MilliporeSigma today launched an industry first—the Mobius MyWay portfolio, a program that allows more flexibility, better supply predictability and shorter lead times for more efficient and safer drug manufacture.
“We have the industry’s only comprehensive single-use solution, giving customers three different ways to create customizable assemblies,” said Andrew Bulpin, Head of Process Solutions Strategic Marketing & Innovation, MilliporeSigma. “This is critical to customers from contract manufacturing organizations to big pharma, whose biggest challenge is getting custom assemblies with fast, reliable lead times for quicker turnarounds and more rapid biomanufacturing.”
For commercial manufacturers, MilliporeSigma’s Mobius MyWay portfolio helps minimize schedule disruptions and delays. Pilot plants benefit from faster assembly design and delivery in order to adjust to new and evolving needs in real-time. Contract manufacturing organizations benefit from more reliable lead times allowing for better planning, which helps ensure on-time product delivery.
MilliporeSigma’s portfolio offers a choice of off-the-shelf and configured-to-order assemblies, as well as fully customizable configurations. Assemblies available as part of the Mobius MyWay portfolio are used for safe and effective fluid management across upstream and downstream processes, from routine buffer and media prep, to critical premium aseptic process and final drug manufacturing.
Assemblies are segmented into three categories, each offering a different level of configuration flexibility:
- Mobius Stock offers on-demand solutions ready to ship in 24 hours.
- Mobius Select offers an optimal balance of speed and configurability of custom assemblies from an optimized component library with an agile 6-week lead time.
- Mobius Choice offers highly customized solutions from our expansive component library, shipped in standard lead times.
Among the assemblies included in the Mobius MyWay portfolio are Mobius MIX systems and bags up to 1,000 liters; holding and transport vessels up to 3,500 liters; Lynx CDR sterile connectors and single-use final formulation, filtration and final fill assemblies.
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
At INTERPHEX 2017 this week, MilliporeSigma representatives are at Booth Nos. 1265 and 2841.
(Source: PR Newswire)
Filed Under: Drug Discovery
